OBJECTIVE: To compare the effects of two intravenous (IV) methotrexate (MTX) infusion protocols on cognitive function in children newly diagnosed with acute lymphoblastic leukemia (ALL). METHODS: We compared 19 children treated with 1 g/m(2) ofIV MTX over 24 hr (Group 1) to 13 children treated with 2 g/m(2) of IV MTX over 4 hr (Group 2) on measures of working memory, nonverbal, and verbal skills shortly after diagnosis (Time 1) and 1 year later (Time 2). RESULTS: A significant GroupxTime interaction was found for a composite measure of working memory with Group 2 declining from Time 1 to Time 2. Group 2 performed significantly worse than Group 1 on a composite measure of nonverbal skills at both time points. CONCLUSIONS: Findings suggest that difficulties in working memory and nonverbal skills may be evident during the first year of treatment for ALL and that severity may be dependent on IV MTX dose and/or infusion rate.
RCT Entities:
OBJECTIVE: To compare the effects of two intravenous (IV) methotrexate (MTX) infusion protocols on cognitive function in children newly diagnosed with acute lymphoblastic leukemia (ALL). METHODS: We compared 19 children treated with 1 g/m(2) of IV MTX over 24 hr (Group 1) to 13 children treated with 2 g/m(2) of IV MTX over 4 hr (Group 2) on measures of working memory, nonverbal, and verbal skills shortly after diagnosis (Time 1) and 1 year later (Time 2). RESULTS: A significant GroupxTime interaction was found for a composite measure of working memory with Group 2 declining from Time 1 to Time 2. Group 2 performed significantly worse than Group 1 on a composite measure of nonverbal skills at both time points. CONCLUSIONS: Findings suggest that difficulties in working memory and nonverbal skills may be evident during the first year of treatment for ALL and that severity may be dependent on IV MTX dose and/or infusion rate.
Authors: Ida M Moore; Marilyn J Hockenberry; Cynthia Anhalt; Kathy McCarthy; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2011-09-21 Impact factor: 3.167
Authors: Kala Y Kamdar; Kevin R Krull; Randa A El-Zein; Pim Brouwers; Brian S Potter; Lynnette L Harris; Suzanne Holm; Zoann Dreyer; Fernando Scaglia; Carol J Etzel; Melissa Bondy; M Fatih Okcu Journal: Pediatr Blood Cancer Date: 2011-05-25 Impact factor: 3.167
Authors: Marilyn J Hockenberry; Olga A Taylor; Patricia M Gundy; Adam K Ross; Alice Pasvogel; David Montgomery; Phillip Ribbeck; Kathy McCarthy; Ida Moore Journal: Biol Res Nurs Date: 2013-08-15 Impact factor: 2.522
Authors: Lea M Ventura; Julie A Grieco; Casey L Evans; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock; Margaret B Pulsifer Journal: J Neurooncol Date: 2017-12-06 Impact factor: 4.130
Authors: Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Neuropsychology Date: 2014-06-16 Impact factor: 3.295
Authors: Joshua E Caron; Kevin R Krull; Marilyn Hockenberry; Neelam Jain; Kris Kaemingk; Ida M Moore Journal: Pediatr Blood Cancer Date: 2009-10 Impact factor: 3.167
Authors: Stephanie L Stenzel; Kevin R Krull; Marilyn Hockenberry; Neelam Jain; Kris Kaemingk; Petra Miketova; Ida M Moore Journal: J Pediatr Hematol Oncol Date: 2010-03 Impact factor: 1.289